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CLINICAL INVESTIGATION
Blood pressure control in normotensive members of
hypertensive families
MARIO G. BIANCHETTI, CARLO BERETTA-PICCOLI, PETER WEIDMANN, and CLAUDIA FERRIER
Medizinische Poliklinik, University of Berne, Switzerland
Selective disturbance of noradrenergic but not angiotensin mediated
blood pressure control in normotensive members of hypertensive families.
The cardiovascular pressor responses to a stepwise increase in plasma
norepinephrine or angiotensin II concentrations, induced by infusions,
were studied in 23 normotensive subjects with a negative and 25 with a
positive family history of essential hypertension. The two study groups
had a similar mean age (24 2 (SD) yr), body weight, blood pressure
(112/64 10/7 mmHg), heart rate, plasma and urinary sodium and
potassium, and plasma norepinephrine, epinephrine, angiotensin II,
renin and aldosterone levels. However, subjects with positive history
differed from those with negative history of hypertension by a de-
creased pressor dose of infused norepinephrine (89 29 vs. 135 66
ng/kg/min; P < 0.005), anda significant (P C 0.01) shift to tbe left of the
relationship between norepinephrine—induced changes in mean arterial
pressure and concomitant changes in plasma norepinephrine. In con-
trast, the relation between stepwise increasing plasma angiotensin II
levels and induced changes in diastolic blood pressure or plasma
aldosterone did not differ significantly between the two study groups.
These findings delineate a distinct abnormality which may often occur
in normotensive offspring of hypertensive families. It is characterized
by a selectively disturbed noradrenergic blood pressure control in the
presence of a normal angiotensin—mediated blood pressure and aldos-
terone regulation.
The development of essential hypertension may be predis-
posed by certain abnormalities in sympathetic-dependent car-
diovascular control mechanisms. Several disturbances have
been reported in normotensive offspring of hypertensive par-
ents and include: a) an exaggerated pressor responsiveness to
exogenous norepinephrine (NE) in the presence of normal
endogenous plasma NE concentrations [11; b) an exaggerated
sensitivity of the forearm vasculature to exogenous NE [2]; c)
an altered baroreceptor function [31; d) an increased respon-
siveness of blood pressure (BP) to mental stress [4]; e) high
plasma catecholamines concentration during stress [41; 1) a
disturbed BP regulation after standing [5]; and g) an abnormal
response of renal plasma flow to psychological stimuli [61.
Whether and to what extent, these aberrations are hereditary
components in the pathogenesis of essential hypertension is
presently unclear [7—10]. An exaggerated cardiovascular re-
sponsiveness to NE or stress could reflect a primary
supersensitivity of the end organ, a secondary abnormality of
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the end organ due to subtle structural abnormalities of the
arterial walls developing in response to mild elevation of BP
[11] and, finally, an altered activity of the sympathetic nervous
system. Moreover, an unspecific hyperreactivity of blood ves-
sels would be reflected by an enhanced pressor—responsiveness
to various stimuli, while a selective defect in catecholamine—
induced reactivity would be characterized by a normal cardio-
vascular responsiveness to non-adrenergic stimuli.
The interaction between non-adrenergic pressor factors and
BP regulation has not yet been evaluated in normotensive
offspring of hypertensive parents. Therefore, the present study
was designed to assess the angiotensin—mediated BP control
before and during infusion of angiotensin II (Ang II) in
normotensive members of hypertensive families as compared
with normotensive members of normotensive families. Since a
simultaneous analysis of both plasma concentrations and car-
diovascular or aldosterogenic effects of Ang II allows a more
integrated assessment of Ang Il—dependent functions, such an
approach was used for the present investigation.
Methods
Twenty-five healthy, non-obese volunteers with a family
history of essential hypertension and 23 healthy, non-obese
volunteers without such a history were studied.
Family history
A family tree was constructed for each subject, and informa-
tion on BP was obtained both by questioning the subjects and
their families and directly from the family doctors and their
medical records. In the group with a positive family history of
hypertension, at least one of both parents or any existing
siblings had essential hypertension; 17 subjects had a parent,
seven both parents, and one a sibling and a parent with
hypertension. In the group without a family history, neither
parent nor any existing siblings had known previous episodes of
high blood pressure; they had a normal BP recorded at least
once in the year preceding the investigation, and there was no
evidence of hypertension in the grandparents, although the
latter information was incomplete in two subjects. Subjects
with an uncertain family history of hypertension and women
taking hormonal contraceptives were excluded from the study.
In hypertensive relatives, secondary forms of hypertension
were excluded by the usual tests [12], including plasma concen-
trations of creatinine, sodium and potassium as well as conven-
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tional urine examination in all, and intravenous urography,
renal angiography, or determination of aldosterone and cate-
cholamine concentrations in a few patients. BP levels were
judged in relation to age and sex, and hypertension was defined
according to Hamilton et a! [10]. To further clarify the role of
heredity in determining the BP responses, the eight subjects
(five females and three males) with both hypertensive parents,
or with one parent and one sibling with essential hypertension,
were matched with eight subjects (four females and four males)
with one hypertensive parent and eight subjects (five females
and three males) without a family history of hypertension.
Study procedure
All subjects were instructed to take a normal diet free of very
salty food and without added salt, beginning at least five days
before the study [13]. All were informed about the investigative
nature of the study and gave their informed consent.
During the 24 hr before the study, urine was collected for
determination of sodium, potassium and creatinine excretion
rates. On the following morning, after an overnight fast, with
the subjects resting supine, an intravenous infusion of 5%
dextrose in water (0.1 mI/mm) was infused slowly for 60 mm,
and BP and heart rate were measured and blood samples
collected through an indwelling intravenous cannula (positioned
at least 30 to 60 mm before on the opposite arm to the infusion)
for determining basal plasma sodium, potassium, creatinine,
renin activity, Ang II, aldosterone, NE and epinephrine levels.
These measurements were obtained between 8 and 10 a.m. The
dextrose infusion was then replaced by a solution of Ang II
(Hypertensin®, CIBA Company, Basle, Switzerland). Ang II
was infused at different rates, which were maintained over 20
mm and increased stepwise. All subjects received at least three
different dose rates of Ang 11(2.1 0.2 (± SD), 4.1 0.5 and
10.4 0.9 ng/kglmin in subjects with a positive family history
and 2.3 0.2, 4.2 0.4 and 10.4 0.9 ng/kglmin in subjects
without a family history); in eight subjects in the first group and
in ten in the second study group, a further infusion step with
20.2 1 or, respectively, 20.3 2.1 ng/kg/min was necessary to
increase the diastolic pressure by at least 20 mmHg. BP and
heart rate were measured every minute during the last 10 mm of
each infusion step, and blood samples were obtained at the end
of each infusion period from the arm contralateral to the
infusion for determination of plasma Ang II and aldosterone
concentrations. In each subject, the cardiovascular pressor
responsiveness to infused NE was also determined, as de-
scribed previously in this study population [1]. All subjects
received at least three different NE dose rates during 20 mm
each. These averaged 20.8 1.8, 41.3 3.6 and 103.5 9.1
nglkglmin in subjects with a family history, 21.2 1.9, 42.4
3.7 and 106.0 9.4 ng/kg/min in the subjects without a family
history. In seven of the subjects with positive family history and
13 of the subjects with negative family history, a further
infusion step with 203 20 ng/kg/min and 202 19 ng/kg/min
was necessary to increase the mean BP by 20 mmHg.
BP was measured with the automatic recorder, Physiometrics
SR 2, which was calibrated against a mercury manometer. Each
value used for analysis was the mean of at least eight measure-
ments. The relation between infused Ang II, plasma concentra-
tions of Ang II, BP, and heart rate was assessed by plotting
curves for the relation between infused Ang II and concomitant
changes in plasma concentration, between Ang II dose rates
and changes in diastolic BP, between Ang TI-induced changes in
diastolic blood pressure and plasma Ang II concentrations
before and during infusion, and between Ang Il-induced
changes in diastolic BP and changes in heart rate. A similar
approach was used for evaluation of NE pressor effects [1]. The
pressor dose of infused Ang II was defined as the dose required
to elevate the diastolic BP by 20 mmHg [14]; the pressor dose of
infused NE was defined as the infused NE dose rate required to
elevate the mean BP by 20 mmHg [1]. Based on previous
demonstration of stable plasma NE or Ang II levels 20 mm after
steady infusion of NE [15, 16] or Ang II [17, 18], their total
plasma clearance was calculated, dividing infusion rates by the
associated changes in plasma NE or Ang II concentration. The
mean of three to four calculated clearances was recorded,
clearance values being comparable during lower and higher
infusion rates [15, 18]. Sodium and potassium were measured
by a flame photometer, creatinine concentration by an autoan-
alyzer [19], plasma renin activity, Ang II and aldosterone levels
by radioimmunoassay [20—22] and plasma NE and epinephrine
concentrations by a radioenzymatic assay [23], as reported
previously from this laboratory [13, 14]. Since natural logarith-
mic transformation rather than absolute values followed a
Gaussian distribution using probability paper [24], the natural
logarithmic transformation of plasma renin activity, plasma Ang
II, NE, doses of infused Ang II or NE and pressor doses of Ang
II or NE was used for statistical analysis. An unpaired (two
tailed) Student's t-test was used for comparison of mean values
between the two study groups, analysis of variance and Bonfer-
roni's test for comparison of mean values between study
subgroups [25], and regression analysis and analysis of
covariance for comparing two regression coefficients [26]. Sig-
nificance was assumed when P <0.05.
Results
Basal findings
The normotensive subjects with and those without a positive
family history of essential hypertension did not differ signifi-
cantly in mean age, body weight, height, BP and heart rate,
plasma levels of sodium, potassium, Ang II, aldosterone, renin,
NE and epinephrine, creatinine clearance, or 24 hr urinary
sodium and potassium excretion rates (Table 1).
Angiotensin II infusion
Plasma Ang II levels measured during Ang II infusion corre-
lated linearly with the corresponding Ang II dose rates; this
correlation was similar in subjects with a positive family history
(r = 0.88; P < 0.001; ln y = 0.91 ln x + 2.74) and in those
without a family history (r = 0.85; P < 0.001; ln y = 0.90 In x
+ 2.88). The calculated total plasma clearances of infused Ang
II were also similar for both study groups (Table 1).
Ang II infused at the lowest dose rate significantly increased
diastolic BP in subjects with (from 64 6 to 72 6 mmHg; P
<0.001) or without (from 64 8 to 70 9 mmHg; P < 0.001)
family history; BP levels measured at the end of the subsequent
Ang II infusion rates were also comparable (77 7, 87 6 and
91 8 mmHg vs. 77 7, 85 7 and 88 6 mmHg).
When the Ang II pressor dose was calculated from the
dose—response curve relating the increments in diastolic BP to
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N
Sex, female/male
Age, years
Blood pressure, mmHg
Heart rate, beats/mm
Height, em
Body weight, kg
Plasma sodium, mmole/l
potassium, mmole/l
renin activity, ng/ml/hr
angiotensin II, pg/mi
aldosterone, ng/dl
norepinephrine, ng/dl
epinephrine, ng/dl
Urinary sodium, mmole/24 hr
potassium, mmole/24 hr
Creatinine clearance,
ml/min/1.73 m2
Pressor dose of infused angioten-
sin Il, ng/kg/min
Pressor dose of infused norepi-
nephrine, ng/kg/min
Total plasma clearance of infused
angiotensin II, mI/mm/kg
Total plasma clearance of infused
norepinephrine, mI/mm/kg
Symbol is: * P < 0.005.
Family history of essential
hypertension
Negative Positive
23
9/1424±4
112/64 10/867±9
174 + 9
66.0 9.5
140,2 1.6
4.0 0.2
1.2 0.7
14.3 5.0
7.2 3.5
17.8 7.4
3.1 1.8
155
71
25
11/1424±2
112/64 10/665±7
175 + 9
65.0 10.8
140.3 2.0
4.1 0.2
1.2 0.6
12.8 5.4
9.5 5.5
19.4 6.8
4.1 0.5
156
71
97 106
11.8 9.3 9.1 5.0
135 83
121 52 120
Ang II infusion rates, this parameter did not differ significantly
between subjects with or without a family history (Table 1).
When the pressor response to infused Ang II was analyzed in
relation to plasma Ang II concentrations, the relationship
between the increases in diastolic BP and the concomitant
changes in plasma Ang TI did not differ significantly between the
two study groups (Fig. 1). Moreover the correlation between
increases in diastolic BP and absolute plasma Ang II levels
measured before and during infusion was also similar. The Ang
II pressor effect was accompanied in both study groups by
similar, significant (P < 0.05) decreases in heart rate at the end
of the first Ang Il—infusion step (— 3 5 versus — 3 6
beats/mm) as well as at the end of the subsequent infusion rates
(— 5 6, — 5 7 and — 8 8 beats/mm versus — 4 8, — 5
10 and — 12 11 beats/mm).
Ang II infused at the lowest dose rate caused a significant (P
<0.001) increase in plasma aldosterone in subjects with (from
9.5 5.5 to 14.9 8.4 ng/dl) or without (from 7.2 3.5 to 13.0
5.1 ngldl) family history of hypertension. Plasma aldosterone
concentrations measured at the end of the subsequent Ang TI
infusion rates were also similar in the two study groups (20.7
8.4, 29.1 11.5 and 36.7 13.0 ng/dl, or respectively, 19.6
8.6, 25.4 11.8 and 36.1 20.3 ng/dl), Thus, the relationship
between increases in plasma aldosterone and plasma Ang II
levels measured before and during infusion, or between in-
creases in plasma aldosterone and concomitant variations in
plasma Ang II (Fig. I) did not differ significantly between
normotensive subjects with or without family history of hyper-
tension. The possible influence of the family history of hyper-
tension on Ang TI-dependent effects was further analyzed by
comparison of Ang II infusions (the three infusion rates that
each subject received) between subgroups containing the eight
subjects having two hypertensive parents or one parent and one
sibling with essential hypertension, eight subjects with one
hypertensive parent and eight subjects without a family history.
Mean basal plasma Ang II and aldosterone levels and the Ang TI
pressor dose did not differ significantly among the three sub-
groups (Table 2). The relationships between stepwise increases
in plasma Ang II and induced changes in BP (Fig. 2) or plasma
aldosterone also did not differ significantly among the sub-
groups.
Norepinephrine infusion
Plasma NE levels measured during NE infusion correlated
linearly with the corresponding NE dose rates. This correlation
was similar in subjects with positive (r — 0.81; P C 0.001; ln y
= 1.01 In x + 0.57) or negative (r = 0.85; P <0.001; In y 0.90
In x 0.71) family history. The increases in circulating NE during
the different infusion steps and the plasma clearance of NE
(Table 1) did not differ significantly between the two study
groups. NE infused at the lowest dose rate significantly in-
creased (P < 0.001) mean BP in subjects with (from 79 7 to 84
6 mmhg) or without (from 78 7 to 82 7 mmHg) a family
history of hypertension; mean BP measured at the end of the
three subsequent NE infusion rates tended to be higher in
subjects with a positive family history than in those with a
negative family history (90 7, 102 10 and 115 12 mmHg
vs. 86 8, 97 8 and 104 9 mmHg). Moreover, the NE
pressor dose, which was calculated from the dose—response
curve relating mean BP to NE infusion rates, was significantly
Table 1. Clinical and biochemical features of normal subjects without
or with a family history of hypertension (mean sD)
Diastolic blood pressure, mmHg Plasma aldnsterone, ng/di
30
20
10
0 I I I — I F I I I
10 20 30 50 100 200 300 10 20 30 50 100 200 300
Plasma angiostensin II, pg/mi
Fig. 1. Relationship between the changes in diastolic blood pressure or
plasma aldosterone and the changes in plasma Ang II concentrations
during Ang 11—infusion in normotensive subjects with or without a
family history of essential hypertension (mean 5EM). Symbols are: 0,
negative family history; •, positive family history.61
86 95 ±50
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Table 2. Some clinical and biochemical features in three subgroups of eight subjects, each with negative family history of essential
hypertension, with one hypertensive parent and with two first degree hypertensive relatives (mean SD)
No hypertensive
parent
One hypertensive
parent
Two hypertensive
first degree relatives
Plasma aldosterone, ng/dl 7.5 4.6 10.7 4.7 10.0 4.5
angiotensin II, pg/mI 15.9 6.1 14.0 3.5 9.3 5.5
Pressor dose of infused angiotensin II, mg/kg/mm 10.9 7.0 8.0 2.7 7.7 2.0
Plasma norepinephrine, ng/dl 20.7 6.3 19.6 8.3 19.6 4.6
Pressor dose of infused norepinephrine, ng/kg/min 156 68 98 37* 69 24
Symbols are: * P < 0.05; and P < 0.01 versus subjects without family history of hypertension.
0
10 20 50 100 200
Plasma angiostensin II, pg/mi
Fig. 2. Relationship between changes in diastolic blood pressure and in
plasma Ang II concentrations in normotensive subjects with or without
a family history of essential hypertension (mean SEM). Symbols are:
0, negative family history; A, positive one parent; •, positive two
parents or one parent plus one sibling.
(P < 0.005) lower in subjects with a positive as compared to
those with a negative family history (Table 1).
When the pressor response to NE was analyzed in relation to
plasma concentrations of NE, the relationship between the
increases in mean BP and in plasma NE was significantly (F =
18.61; P < 0.01) displaced to the left in subjects with a positive
family history as compared to those with negative history (Fig.
3). The correlation between NE—induced increases in mean BP
and corresponding absolute NE plasma levels before and during
infusion also was displaced in the group with positive history (F
= 14.60; P < 0.01). The pressor response to NE was associated
with a significant dose dependent fall in heart rate. The rela-
tionship between the NE—induced fall in heart rate and the
increase in mean BP did not differ between the two study
groups. Mean basal plasma NE levels did not differ between
subgroups, including eight subjects with two hypertensive
parents or one parent and one sibling with hypertension, the
eight matched subjects with only one hypertensive parent and
Diastolic blood pressure, mmHg30 -
20 -
10-
40 - Mean blood pressure, mmHg
30 -
20 -
10
0-
10 20 50 100 200 500 ng/di
Plasma norepinephrine
Fig. 3. Relationship between changes in mean arterial pressure and in
plasma norepinephrine concentrations during norepinephrine infusion
in normotensive subjects with or without a family history of essential
hypertension (mean sEM). Modified from [11. Symbols are: 0,
negative family history; I, positive family history.
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offspring of one hypertensive and one normotensive parent.
The present study complements the profile of cardiovascular
reactivity in offspring of hypertensive families by providing
information on Ang H—mediated BP control. In contrast to the
noradrenergic regulation, the pressor and steroidogenic re-
sponses to stepwise increases in circulating Ang II did not differ
significantly between normotensive subjects with positive or
negative family history of essential hypertension. These find-
ings suggest that the exaggerated pressor responsiveness to NE
in normotensive offspring of hypertensive families does not
reflect an unspecific, secondary hyperreactivity state due to
pre-existing structural vascular abnormalities of blood vessels
[11], but seems to be a selective primary disturbance in norad-
renergic vascular regulation. Furthermore, the tendency for an
increasing degree of abnormality with increasing number of
affected family members may be consistent with an inherited
rather than an environmental cause [81.
In an earlier report the sensitivity of forearm blood flow to
NE was increased in normotensive sons of hypertensive par-
ents [21; however, concomitant measurements of endogenous
plasma norepinephrine were unavailable and Ang Il—dependent
BP control was not assessed. Both aspects are important for
interpretation, since the sympathetic and renin—angiotensin
system may modulate each other [27], and pressor responses to
NE or Ang II correlated inversely with their basal plasma
concentrations in normotensive man [28, 29] as well as in
patients with mild or moderate essential hypertension [28, 291.
In our normotensive subjects, the endogenous plasma NE
concentration was normal, unrelated to the family history of
essential hypertension, and similar to the values previously
observed [13, 30, 311; the heart rate and plasma levels of
epinephrine and renin activity were also unchanged. This
suggests that the basal adrenergic tone was not altered in
normotensive subjects with a family history of hypertension.
On the other hand, the pressor responsiveness to NE was
clearly abnormal in the subjects with one or two hypertensive
parents; this was confirmed by a highly significant decrease of
the NE pressor dose, and by a significant shift to the left of the
relationship between NE induced variations in BP and concom-
itant changes in circulating NE. The difference in BP response
was already present at plasma levels of NE which could be
measured under conditions of adrenergic activation such as
exercise [30].
In contrast to this abnormality, the activity of the renin—angi-
otensin system, as judged by plasma renin and Ang II levels,
and the responsiveness of both BP and plasma aldosterone
concentrations to Ang II were all normal in the subjects with or
without a family background for hypertension. The latter ob-
servation further suggests an unaltered relationship between
endogenous activity and target organ sensitivity of Ang II.
Several factors may modify pressor responses. Exaggerated
responsiveness could result from excessive sodium intake, low
potassium intake, increased extracellular content of sodium
diminished baroreflex function, or altered metabolism of in-
fused NE [31—371. The dietary intake of sodium and potassium,
as judged by 24 hr urinary excretion of these electrolytes also
did not differ between study groups. Moreover, a tendency for
low blood volume, reported previously in normotensive mem-
bers of hypertensive families 1321, would be expected to blunt
rather than enhance the pressor response to pressor agents [35,
iS Mean blood pressure, mml-Ig30—
20 -
10 -
0 I I I I I
5 10 20 30 50 100 200 300 ng/dl
5 Plasma norepinephrine
Fig. 4. Relationship between changes in mean arterial pressure and
plasma norepinephrine concentrations in normotensive subjects with or
without a family history of essential hypertension (mean 5EM).
Symbols are: 0, negative family history; A, positive ane parent; U,
positive two parents or one parent plus one sibling.
the eight subjects with a negative family history (Table 2).
However, the mean NE pressor dose differed among the three
subgroups, being significantly lower in the two history—positive
subgroups than in the history—negative subjects (P < 0.01 and P
< 0.05, respectively). The relationship between NE—induced
increases in mean BP and concomitant increases in plasma NE
was also significantly displaced to the left in the two
history—positive subgroups (F 14.68 and 16.22, respectively;
P <0.01; Fig. 4). Moreover, the plasma NE pressor—response
curve in these two history positive subgroups was quite similar
at lower NE infusion rates, however, the pressor response to
the highest NE tended to be greater in the subgroup with two
than in that with one hypertensive first—degree relative.
Discussion
In the present study, normotensive subjects with positive
family history of essential hypertension reacted to a stepwise
increase in circulating NE with an exaggerated rise in BP,
although their basal levels of plasma NE and BP did not differ
from those in the control group [11. Moreover, at higher NE
infusion rates, this abnormality tended to be more marked in
subjects with two hypertensive first degree relatives than in
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36]. Since NE exerts a peripheral and cardiac action, an exact
assessment of baroreflex function could not be made during NE
infusion. Nevertheless, the similarity of the negative chrono-
tropic heart rate response to NE—induced increases in BP in our
subjects with or without a family history of essential hyperten-
sion and the normal cardiovascular responses to Ang II strongly
indicate that the exaggerated pressor reactivity to NE in off-
spring from hypertensive families could not be explained by a
defect baroreflex or an altered body electrolyte fluid volume
state. Subtle abnormalities in the regulation of renin secretion,
with a high plasma renin activity under certain experimental
conditions, have been reported in normotensive members of
hypertensive families [38—40]. Such a tendency should blunt the
pressor and adrenal effects of Ang II [40, 41]; this was not
observed in the present investigation in our subjects studied
under basal conditions. The selective hyperreactivity to NE in
the relatives of hypertensives also could not be explained by a
different metabolism of infused NE. In the present study, NE
was infused at constant rate during 20 mm; in previous studies
a stable plasma concentration of NE was reached already after
5 mm, and was maintained up to 30 mm of infusion [15]. Under
these conditions the infusion rate—blood level curves and the
calculated clearance values were unaltered in subjects with a
family history of hypertension [I]. Finally, a causative role of
hypertension—induced structural or functional changes in the
blood vessel walls [11] seems largely excluded. In fact, the BP
was similar in the study groups, no subject had known previous
episodes of hypertension and a variation in vessel geometry
would result in a generalized hyperreactivity to all pressor
agents, including angiotensin II [11].
Hypertensive families may possibly carry an abnormality in
cation transport across cell membranes. Whether some ob-
served defects in blood cells reflect a more generalized distur-
bance also affecting vascular smooth muscle cells remains to be
clarified [42—50]. Nevertheless, such a mechanism could lead to
an increased availability of sodium and calcium [46—50].Apart
from binding to specific receptors, NE and Ang II seem to exert
their pressor effect by a somewhat different interaction with
these cations. The NE—induced contraction depends on calcium
deriving from transmembranous influx through the "slow"
channels as well as release from intracellular and binding sites
[51, 52]. In contrast, the Ang IT—induced contraction requires
the cellular influx of sodium [52]. Certain clinical observations
with calcium antagonist complement this notion [14]. Whatever
the exact underlying cellular mechanism, the constellation of
selective hyperresponsiveness to NE in the presence of a
normal Ang Il—dependent BP regulation may well be a familial
and possibly hereditary disturbance which predisposes for the
development of essential hypertension.
Adrenal responsiveness to Ang II may be altered in patients
with essential hypertension. Aldosterone responsiveness to
infused Ang II was found to be enhanced [18, 53], normal [54,
551, oreven blunted [56] in patients with essential hypertension.
Such discrepancies may be, at least in part, accounted by
differences in basal plasma renin activity [411, in dietary condi-
tions of sodium and potassium intake [34, 36] or in the protocol
of the Ang II infusion studies. Moreover, it appears possible
that patients with essential hypertension may have an abnormal
adaptation of aldosterone production to variations in sodium
intake. The present study was conducted on a normal dietary
intake of sodium and potassium; under these conditions the
effect of an acute Ang II infusion on adrenal aldosterone release
was normal in normotensive offspring of hypertensive families.
It appears possible that abnormalities in aldosterone regulation
by Ang II, whenever present, may develop during the course of
essential hypertension rather than represent a primary distur-
bance.
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